MYC amplifies mitotic perturbations elicited by LXY18 to enable synthetic lethality
Yang, D.; Kalashova, J.; Yang, C.; Long, Y.; Li, H.; Zhang, S.; Zhang, T.; Yu, D.; Liu, X.; Lv, G.; Choudhry, N.; Liu, H.; Shi, Q.
Show abstract
The MYC oncoprotein represents an intriguing target for cancer treatment, but its therapeutic potential has been hindered by the absence of specific pharmacological inhibitors. In this study, we demonstrate that the phenoxy quinoline compound LXY18 selectively targets and eliminates cells overexpressing MYC, leaving non-transformed cells unharmed. This synthetic lethality arises from an acute induction of multipolarity, resulting in a persistent arrest in early mitosis followed by cell death in mitosis or after mitotic slippage. Distinctively, LXY18s action contrasts with other antimitotic compounds, as they either fail to induce mitotic arrest or elicit mitotic arrest irrespective of MYC abundance. Furthermore, the MYC abundance in a panel of 98 tumor cell lines correlates with their sensitivity to LXY18. Collectively, our findings uncover LXY18 as an MYC- enabled mitotic blocker and open a new avenue to selectively target MYC-overexpressing tumor cells without affecting normal cells.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma 96%
- Inhibiting BCKDK in triple-negative breast cancer suppress protein translation, impair mitochondrial function, and potentiate doxorubicin cytotoxicity 94%
- Improving the power of drug toxicity measurements by quantitative nuclei imaging 93%
Similar papers in this journal
- Collateral Responses to Classical Cytotoxic Chemotherapies are Heterogeneous and Sensitivities are Sparse 94%
- Epithelial-mesenchymal transition sensitizes breast cancer cells to cell death via the fungus-derived sesterterpenoid ophiobolin A 94%
- PKIS Deep Dive Yields a Chemical Starting Point for Dark Kinases and a Cell Active BRSK2 Inhibitor 94%
Similar papers in this journal
- Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death 95%
- Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1 94%
- Mitoxantrone inhibits and downregulates ERα through binding at the DBD-LBD interface 93%
Similar papers in this journal
Similar papers in this journal
- Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells 95%
- A subset of CB002 xanthine analogues bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53 94%
- Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.